Samson Baranzan Wayah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samson Baranzan Wayah has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kensuke Arakawa
Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan
2 shared publications Koshy Philip
2 shared publicationsPeter Maitalata Waziri
Department of Biochemistry Faculty of Pure and Applied Sciences Kaduna State University Nigeria
2 shared publications- Amos Alvan
Department of Biochemistry, Faculty of Pure and Applied Sciences, Kaduna State University, Nigeria
1 shared publication Atika Abubakar-Garba Faila
Department of Biochemistry, Faculty of Pure and Applied Sciences, Kaduna State University, Nigeria
1 shared publicationEmmanuel Haruna
Department of Biochemistry, Faculty of Science, Kaduna State University, Nigeria
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by Elsevier in Current Research in Microbial Sciences
- Vol. 11
From predicted bacteriocins to ecological function
- 11 September 2026
- Published by Elsevier in Current Research in Microbial Sciences
- Vol. 11
Open AccessFrom predicted bacteriocins to ecological function
- Open Access
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1875597
Bacteriocins from Limosilactobacillus and Ligilactobacillus: ecological logic, mechanistic diversity, and translational potential in the post-Lactobacillus taxonomy
Bacteriocins are ribosomally synthesized antimicrobial peptides that contribute to microbial competition, niche establishment, and community structure. The 2020 taxonomic reorganization of the former broad Lactobacillus genus provides a useful framework for reinterpreting bacteriocin diversity in lineage-specific ecological contexts. This review focuses on bacteriocins produced by species now assigned to Limosilactobacillus and Ligilactobacillus , two host- and food-associated genera that include several reported bacteriocin producers. These genera were selected because they contain bacteriocins with diverse structural features, including cyclic peptides, class IIa and IIb peptides, class IId peptides, defensin-like peptides, and larger proteinaceous bacteriocins, and because many producer strains originate from competitive ecological niches such as the gastrointestinal tract, oral cavity, vagina, milk, poultry, livestock, and fermented foods. We synthesize evidence on bacteriocin biosynthetic gene clusters, molecular diversity, antimicrobial mechanisms, ecological functions, physicochemical stability, and translational potential. This review also distinguishes bacteriocin-specific evidence from effects attributable to bacteriocin-producing strains, particularly for immunomodulation, co-aggregation, pathogen exclusion, and microbiota modulation. Finally, we address how comparative genomics, structured genome mining and artificial intelligence-aided prediction can speed bacteriocin discovery, emphasizing the necessity of experimental validation, standardized activity assays, safety evaluation and scalable production. This study gives a systematic framework to understand the bacteriocins of Limosilactobacillus and Ligilactobacillus in the post- Lactobacillus era by integrating taxonomy, ecology, mechanism and translational evidence.
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1875597
Open AccessBacteriocins from Limosilactobacillus and Ligilactobacillus: ecological logic, mechanistic diversity, and translational potential in the post-Lactobacillus taxonomy
Bacteriocins are ribosomally synthesized antimicrobial peptides that contribute to microbial competition, niche establishment, and community structure. The 2020 taxonomic reorganization of the former broad Lactobacillus genus provides a useful framework for reinterpreting bacteriocin diversity in lineage-specific ecological contexts. This review focuses on bacteriocins produced by species now assigned to Limosilactobacillus and Ligilactobacillus , two host- and food-associated genera that include several reported bacteriocin producers. These genera were selected because they contain bacteriocins with diverse structural features, including cyclic peptides, class IIa and IIb peptides, class IId peptides, defensin-like peptides, and larger proteinaceous bacteriocins, and because many producer strains originate from competitive ecological niches such as the gastrointestinal tract, oral cavity, vagina, milk, poultry, livestock, and fermented foods. We synthesize evidence on bacteriocin biosynthetic gene clusters, molecular diversity, antimicrobial mechanisms, ecological functions, physicochemical stability, and translational potential. This review also distinguishes bacteriocin-specific evidence from effects attributable to bacteriocin-producing strains, particularly for immunomodulation, co-aggregation, pathogen exclusion, and microbiota modulation. Finally, we address how comparative genomics, structured genome mining and artificial intelligence-aided prediction can speed bacteriocin discovery, emphasizing the necessity of experimental validation, standardized activity assays, safety evaluation and scalable production. This study gives a systematic framework to understand the bacteriocins of Limosilactobacillus and Ligilactobacillus in the post- Lactobacillus era by integrating taxonomy, ecology, mechanism and translational evidence.
- Open Access
- 1 April 2025
- Published by Nigerian Medical Association, Akwa Ibom State Branch in Ibom Medical Journal
- Vol. 18 (2) , 249-260
Harnessing the Potential of Bacteriocin in the Treatment of Typhoid Fever and Cholera: A Systematic Review
Background: Typhoid fever kills 135,000 to 230,000 people every year and affects an estimated 11–21 million people globally. About 95,000 people die annually from cholera, and an additional 2.86 million get infected. Bacteriocins have been reported to inhibit the growth of various pathogens such as Salmonella typhi and Vibrio cholerae. Objective: The aim of the study was to identify bacteriocins having potential in treating typhoid fever and cholera. Methods: The techniques utilized in this study adhere to the recommended reporting items for systematic reviews and meta-analysis (PRISMA) framework for systematic review. These methods encompass the processes of identification, screening, eligibility, and inclusion. Results: A total of 13,012 literatures were obtained from google scholar and PubMed. After removal of duplicates, and screening of title, abstract and full-text, a total 34 articles were used for data extraction. Multiple lactic acid bacteria capable of producing highly effective bacteriocins against typhoid and cholera were found. Bacteriocins with potential to combat typhoid include enterocin LD3, bacteriocin DU10, bacteriocin LD4, plantaricin LP 21–2, plantaricin SLG1, enterocin B, enterocin A, plantaricin LD1, plantaricin JLA-9, bacteriocin LJR1, and bacteriocin LB44. Bacteriocins with potential to mitigate cholera include pediocin PA-1, enterocin 12a, and a silver nanoparticle-based bacteriocin. These bacteriocins act against etiological agents of typhoid fever and cholera by pore formation, destruction of cell wall and bactericidal action. Conclusion Several anti-typhoid and anti-cholera bacteriocins have been identified. Further investigation into their modes action against Salmonella typhi and Vibrio cholerae is needed. Additionally, in vivo assessment of their potency in treating typhoid fever and cholera is urgently required.
- 1 April 2025
- Published by Nigerian Medical Association, Akwa Ibom State Branch in Ibom Medical Journal
- Vol. 18 (2) , 249-260
Open AccessHarnessing the Potential of Bacteriocin in the Treatment of Typhoid Fever and Cholera: A Systematic Review
Background: Typhoid fever kills 135,000 to 230,000 people every year and affects an estimated 11–21 million people globally. About 95,000 people die annually from cholera, and an additional 2.86 million get infected. Bacteriocins have been reported to inhibit the growth of various pathogens such as Salmonella typhi and Vibrio cholerae. Objective: The aim of the study was to identify bacteriocins having potential in treating typhoid fever and cholera. Methods: The techniques utilized in this study adhere to the recommended reporting items for systematic reviews and meta-analysis (PRISMA) framework for systematic review. These methods encompass the processes of identification, screening, eligibility, and inclusion. Results: A total of 13,012 literatures were obtained from google scholar and PubMed. After removal of duplicates, and screening of title, abstract and full-text, a total 34 articles were used for data extraction. Multiple lactic acid bacteria capable of producing highly effective bacteriocins against typhoid and cholera were found. Bacteriocins with potential to combat typhoid include enterocin LD3, bacteriocin DU10, bacteriocin LD4, plantaricin LP 21–2, plantaricin SLG1, enterocin B, enterocin A, plantaricin LD1, plantaricin JLA-9, bacteriocin LJR1, and bacteriocin LB44. Bacteriocins with potential to mitigate cholera include pediocin PA-1, enterocin 12a, and a silver nanoparticle-based bacteriocin. These bacteriocins act against etiological agents of typhoid fever and cholera by pore formation, destruction of cell wall and bactericidal action. Conclusion Several anti-typhoid and anti-cholera bacteriocins have been identified. Further investigation into their modes action against Salmonella typhi and Vibrio cholerae is needed. Additionally, in vivo assessment of their potency in treating typhoid fever and cholera is urgently required.
- Open Access
- 31 March 2025
- Published by Federal University Dutsin-Ma in FUDMA JOURNAL OF SCIENCES
- Vol. 9 (3) , 358-365
ISOLATION AND CHARACTERIZATION OF PYOCIN S2-PRODUCING LOCAL STRAINS OF Pseudomonas aeruginosa
Antibiotic resistance is responsible for 1.27 million deaths globally. Pyocin, from Pseudomonas aeruginosa is a promising candidate against antibiotic-resistant infections. This study aims at isolating pyocin S2-producing local strains of Pseudomonas aeruginosa and investigating the antimicrobial activity of pyocin S2 against Staphylococcus aureus, Staphylococcus sp., Escherichia coli, Salmonella sp., Streptococcus pneumoniae, and Vibrio cholerae. Pseudomonas aeruginosa was isolated from environmental and clinical samples by inoculation on cetrimide agar plates and incubating at 370C for 24 hours. To detect the presence of pyocin S2 gene in the isolates: DNA extraction, polymerase chain reaction (PCR) using primers specific to pyocin S2 gene, and agarose gel electrophoresis was conducted. Using agar well diffusion assay, the antimicrobial activity of pyocin S2-containing Pseudomonas aeruginosa against the aforementioned target pathogens was evaluated. Out of 20 Pseudomonas aeruginosa isolates subjected to PCR, 11 contained pyocin S2 gene. Pyocin S2 from Pseudomonas aeruginosa A1, B2, CL2, CL8 and C11 produced zone of inhibition (ZOI) when tested against Escherichia coli (ZOI = 23.5mm, 17.5mm, 26.0mm, 21.5mm, 29.0mm respectively). However, pyocin S2 from Pseudomonas aeruginosa B3, B10, CL3, B19, CL9 and CL6 did not inhibit Escherichia coli but suppressed the growth of Staphylococcus sp. (ZOI = 21.0mm, 18.5mm, 28.5mm, 23.7mm, 24.5mm and 23.5mm respectively). Also, Pyocin S2 from Pseudomonas aeruginosa C11 suppressed the growth of Vibrio cholerae (ZOI = 30.7mm), but not the other strains. In conclusion, pyocin S2 from indigenous strains of Pseudomonas aeruginosa inhibited the target pathogens. These findings will foster further evaluation of pyocin S2’s antimicrobial potential.
- 31 March 2025
- Published by Federal University Dutsin-Ma in FUDMA JOURNAL OF SCIENCES
- Vol. 9 (3) , 358-365
Open AccessISOLATION AND CHARACTERIZATION OF PYOCIN S2-PRODUCING LOCAL STRAINS OF Pseudomonas aeruginosa
Antibiotic resistance is responsible for 1.27 million deaths globally. Pyocin, from Pseudomonas aeruginosa is a promising candidate against antibiotic-resistant infections. This study aims at isolating pyocin S2-producing local strains of Pseudomonas aeruginosa and investigating the antimicrobial activity of pyocin S2 against Staphylococcus aureus, Staphylococcus sp., Escherichia coli, Salmonella sp., Streptococcus pneumoniae, and Vibrio cholerae. Pseudomonas aeruginosa was isolated from environmental and clinical samples by inoculation on cetrimide agar plates and incubating at 370C for 24 hours. To detect the presence of pyocin S2 gene in the isolates: DNA extraction, polymerase chain reaction (PCR) using primers specific to pyocin S2 gene, and agarose gel electrophoresis was conducted. Using agar well diffusion assay, the antimicrobial activity of pyocin S2-containing Pseudomonas aeruginosa against the aforementioned target pathogens was evaluated. Out of 20 Pseudomonas aeruginosa isolates subjected to PCR, 11 contained pyocin S2 gene. Pyocin S2 from Pseudomonas aeruginosa A1, B2, CL2, CL8 and C11 produced zone of inhibition (ZOI) when tested against Escherichia coli (ZOI = 23.5mm, 17.5mm, 26.0mm, 21.5mm, 29.0mm respectively). However, pyocin S2 from Pseudomonas aeruginosa B3, B10, CL3, B19, CL9 and CL6 did not inhibit Escherichia coli but suppressed the growth of Staphylococcus sp. (ZOI = 21.0mm, 18.5mm, 28.5mm, 23.7mm, 24.5mm and 23.5mm respectively). Also, Pyocin S2 from Pseudomonas aeruginosa C11 suppressed the growth of Vibrio cholerae (ZOI = 30.7mm), but not the other strains. In conclusion, pyocin S2 from indigenous strains of Pseudomonas aeruginosa inhibited the target pathogens. These findings will foster further evaluation of pyocin S2’s antimicrobial potential.
- Open Access
- 25 January 2025
- Published by African Journals Online (AJOL) in Dutse Journal of Pure and Applied Sciences
- Vol. 10 (4c) , 1-13
Evaluation of the roles of Mex genes in antibiotic resistance of some strains of Pseudomonas aeruginosa and the use of antibiotic combinations to boost their susceptibility pattern
Pseudomonas aeruginosa is a prevalent pathogen responsible for various infections, and exhibits significant resistance to a broad spectrum of antibiotics, leading to increased mortality rates. This study aimed to assess the role of mex genes in antibiotic resistance among indigenous strains of Pseudomonas aeruginosa and enhance their susceptibility through antibiotic combinations. Ten isolates were selected based on their appearance on selective media, microscopy and biochemical characterization. Antibiotic resistance profiles for fluoroquinolones (ofloxacin, pefloxacin, sparfloxacin, ciprofloxacin), aminoglycosides (gentamicin, streptomycin), beta-lactams (amoxicillin) Sulfonamide (septrin) and Macrolide (septrin) were determined using the Bauer-Kirby disk diffusion method. Minimum inhibitory concentrations (MICs) for 13 individual antibiotics and 19 combined antibiotics were determined using two-fold serial dilution techniques. DNA was extracted from P. aeruginosa isolates and analyzed by polymerase chain reaction (PCR) to detect resistance genes- MexA, MexB, and MexZ. The MexA and MexZ resistance genes were detected in all isolates, while MexB was present in all except 3 of the isolates. P. aeruginosa exhibited the highest susceptibility to gentamicin (40%) and complete resistance to sparfloxacin (100%). The multiple antibiotic resistance (MAR) index ranged from 0.22 to 1. The MIC values for cefexime and ciprofloxacin was 128 µg/mL, while ciprofloxacin + amoxicillin was 32 µg/mL showing increased susceptibility. This study highlights the presence of highly resistant P. aeruginosa strains, it showed a relationship between the resistant genes and antibiotic resistance. Drug combination of ciprofloxacin and amoxicillin proved to be most susceptible against the pathogen. This brings the need to study the mechanism of resistance in the pathogen and target silencing these resistance genes. There should be sensitization, increased awareness among patients and healthcare providers regarding the rising antibiotic resistance of the strain.
- 25 January 2025
- Published by African Journals Online (AJOL) in Dutse Journal of Pure and Applied Sciences
- Vol. 10 (4c) , 1-13
Open AccessEvaluation of the roles of Mex genes in antibiotic resistance of some strains of Pseudomonas aeruginosa and the use of antibiotic combinations to boost their susceptibility pattern
Pseudomonas aeruginosa is a prevalent pathogen responsible for various infections, and exhibits significant resistance to a broad spectrum of antibiotics, leading to increased mortality rates. This study aimed to assess the role of mex genes in antibiotic resistance among indigenous strains of Pseudomonas aeruginosa and enhance their susceptibility through antibiotic combinations. Ten isolates were selected based on their appearance on selective media, microscopy and biochemical characterization. Antibiotic resistance profiles for fluoroquinolones (ofloxacin, pefloxacin, sparfloxacin, ciprofloxacin), aminoglycosides (gentamicin, streptomycin), beta-lactams (amoxicillin) Sulfonamide (septrin) and Macrolide (septrin) were determined using the Bauer-Kirby disk diffusion method. Minimum inhibitory concentrations (MICs) for 13 individual antibiotics and 19 combined antibiotics were determined using two-fold serial dilution techniques. DNA was extracted from P. aeruginosa isolates and analyzed by polymerase chain reaction (PCR) to detect resistance genes- MexA, MexB, and MexZ. The MexA and MexZ resistance genes were detected in all isolates, while MexB was present in all except 3 of the isolates. P. aeruginosa exhibited the highest susceptibility to gentamicin (40%) and complete resistance to sparfloxacin (100%). The multiple antibiotic resistance (MAR) index ranged from 0.22 to 1. The MIC values for cefexime and ciprofloxacin was 128 µg/mL, while ciprofloxacin + amoxicillin was 32 µg/mL showing increased susceptibility. This study highlights the presence of highly resistant P. aeruginosa strains, it showed a relationship between the resistant genes and antibiotic resistance. Drug combination of ciprofloxacin and amoxicillin proved to be most susceptible against the pathogen. This brings the need to study the mechanism of resistance in the pathogen and target silencing these resistance genes. There should be sensitization, increased awareness among patients and healthcare providers regarding the rising antibiotic resistance of the strain.
- Open Access
- 30 December 2024
- Published by Umaru Musa YarAdua University Katsina NG in UMYU Journal of Microbiology Research (UJMR)
- Vol. 9 (2) , 240-248
Development of New Media for the Production of Bacteriocin from Weissella cibaria man1
According to the World Health Organization, antibiotic resistance is one of the top ten global health challenges. Bacteriocins from lactic acid bacteria are widely considered viable alternatives to antibiotics. However, one of the obstacles to bacteriocin commercialization is low yield. In order to circumvent this challenge, it is essential to enhance our understanding of the factors that impact bacteriocin production. Therefore, a study aimed at developing cost-effective media for bacteriocin production from Weissella cibaria man1 was carried out. Media were developed from cheap indigenously sourced materials. Bacteriocin production was measured by agar well diffusion assay. Multiple cost-effective media for the efficient production of bacteriocin from Weissella cibaria man1 were developed. It was discovered that culture media had significant effect (p ˂ 0.05) on the production of bacteriocin by Weissella cibaria man1. One of the newly developed media, APC, produced the highest level of bacteriocin. The APC medium produced bacteriocin at a level significantly higher than the commercial medium, MRS broth. Moreover, bacteriocin production in 6 additional, newly developed media namely, DAT, BAE, DAC, CAN, PIN, RIG was as high as that of MRS broth. Bacteriocin synthesis by Weissella cibaria man1 was greatly influenced by the starting pH of the APC culture medium. Furthermore, optimum level of bacteriocin was observed at pH values of 5 and 6. The industrial production of bacteriocin from bacteriocinogenic lactic acid bacteria for use in medicinal applications will be substantially facilitated as a result of these discoveries.
- 30 December 2024
- Published by Umaru Musa YarAdua University Katsina NG in UMYU Journal of Microbiology Research (UJMR)
- Vol. 9 (2) , 240-248
Open AccessDevelopment of New Media for the Production of Bacteriocin from Weissella cibaria man1
According to the World Health Organization, antibiotic resistance is one of the top ten global health challenges. Bacteriocins from lactic acid bacteria are widely considered viable alternatives to antibiotics. However, one of the obstacles to bacteriocin commercialization is low yield. In order to circumvent this challenge, it is essential to enhance our understanding of the factors that impact bacteriocin production. Therefore, a study aimed at developing cost-effective media for bacteriocin production from Weissella cibaria man1 was carried out. Media were developed from cheap indigenously sourced materials. Bacteriocin production was measured by agar well diffusion assay. Multiple cost-effective media for the efficient production of bacteriocin from Weissella cibaria man1 were developed. It was discovered that culture media had significant effect (p ˂ 0.05) on the production of bacteriocin by Weissella cibaria man1. One of the newly developed media, APC, produced the highest level of bacteriocin. The APC medium produced bacteriocin at a level significantly higher than the commercial medium, MRS broth. Moreover, bacteriocin production in 6 additional, newly developed media namely, DAT, BAE, DAC, CAN, PIN, RIG was as high as that of MRS broth. Bacteriocin synthesis by Weissella cibaria man1 was greatly influenced by the starting pH of the APC culture medium. Furthermore, optimum level of bacteriocin was observed at pH values of 5 and 6. The industrial production of bacteriocin from bacteriocinogenic lactic acid bacteria for use in medicinal applications will be substantially facilitated as a result of these discoveries.
- 4 August 2020
- Published by Wolters Kluwer Health in Reviews and Research in Medical Microbiology
- Vol. 32 (2) , 67-74
New insights on potential therapeutic options and vaccines for corona virus disease-2019
In December 2019, world health organization was acquainted of the outbreak of pneumonia of unknown cause. The causative agent was identified as a novel coronavirus and named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the disease coronavirus disease-19 (COVID-19). This disease is a pandemic, which has so far, caused more than 376 320 deaths globally. Owing to the high transmission and mortality of COVID-19, identifying ways to circumvent the imbroglio has become the top priority of researchers across different parts of the world. To date, no treatment or preventive approach has been developed. Two approaches can be employed to solve the conundrum, a curative/therapeutic and a preventive approach. The therapeutic approach can be divided into two aspects, blocking various aspects of viral entry into target cells and completion of its life cycle using antiviral drugs whereas the second aspect involves modification of host immune responses and inhibition of cell surface receptors and enzymes required for SARS-CoV-2 infection. The preventive approach involves the development of vaccines. Recent advances in the development of drugs targeting host cell receptors and enzymes, SARS-CoV-2-specific antibodies, immunomodulatory drugs, and vaccines have been discussed in this review.
- 4 August 2020
- Published by Wolters Kluwer Health in Reviews and Research in Medical Microbiology
- Vol. 32 (2) , 67-74
New insights on potential therapeutic options and vaccines for corona virus disease-2019
In December 2019, world health organization was acquainted of the outbreak of pneumonia of unknown cause. The causative agent was identified as a novel coronavirus and named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the disease coronavirus disease-19 (COVID-19). This disease is a pandemic, which has so far, caused more than 376 320 deaths globally. Owing to the high transmission and mortality of COVID-19, identifying ways to circumvent the imbroglio has become the top priority of researchers across different parts of the world. To date, no treatment or preventive approach has been developed. Two approaches can be employed to solve the conundrum, a curative/therapeutic and a preventive approach. The therapeutic approach can be divided into two aspects, blocking various aspects of viral entry into target cells and completion of its life cycle using antiviral drugs whereas the second aspect involves modification of host immune responses and inhibition of cell surface receptors and enzymes required for SARS-CoV-2 infection. The preventive approach involves the development of vaccines. Recent advances in the development of drugs targeting host cell receptors and enzymes, SARS-CoV-2-specific antibodies, immunomodulatory drugs, and vaccines have been discussed in this review.